# Test-retest Evaluation of [18F]F-AraG PET

Source: https://onco.cc/trials/nct06084806/  
OnCo record `nct06084806` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of [18F]F-ARAG PET in non-small-cell lung cancer, run by CellSight Technologies, Inc., now recruiting.

## Summary

Test-retest Evaluation of [18F]F-AraG PET is a phase 2 interventional study registered as NCT06084806 by CellSight Technologies, Inc., with 10 participants planned, started 2023-10-31 and due to reach its primary completion in 2025-10-31. Interventions recorded: [18F]F-ARAG PET.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06084806
- Phase: 2
- Setting: Test-retest Evaluation of [18F]F-AraG PET in Non-small Cell Lung Cancer (NSCLC) Patients
- Sponsor: CellSight Technologies, Inc.
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT06084806: https://clinicaltrials.gov/study/NCT06084806

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct06084806.json